← All educational resources

Small Fiber Neuropathy: The Pain, Burning, and Fainting Problem That Hides Behind Normal Nerve Tests

2026-11-22

Same post, two depths. Switch any time; the research version has the enzyme names, lab markers, and doses. Written from a research and education perspective: a model of what may be going on and what the published literature suggests would address it if the model is right, not medical advice or a treatment plan.

Burning feet at night. Pins and needles that move around. Skin that hurts when the sheet touches it. A heart that races on standing, sweating that is wrong (too much, too little, or in patches), bowels that stall, and a gnawing fatigue. Then a nerve conduction study, which is the standard nerve test, comes back normal, and the conclusion is "nothing wrong with your nerves."

The standard test only measures the large nerves, the fat, insulated ones that carry movement and position sense. The nerves that carry pain, temperature, itch, and every automatic signal to your heart, gut, sweat glands, and blood vessels are the small fibers, and they are invisible to that test. Small fiber neuropathy is damage to those. It is common, it is under-diagnosed, it is behind a large share of fibromyalgia, POTS, and "unexplained" chronic pain, and the point of this page is that it has causes you can look for and, in many cases, repair.

What small fibers do

Think of the nervous system as having thick cables and thin wires. The thick cables (large fibers) carry commands to muscles and the sense of where your limbs are. The thin wires (small fibers, the A-delta and C fibers) carry:

  • Pain and temperature from the skin
  • Itch
  • Deep, aching, "sick" pain from organs and muscle
  • The autonomic signals: heart rate, blood vessel tone, sweating, pupil size, gut motility, bladder, and the gland secretions that keep eyes and mouth wet

Damage them and you get two kinds of symptom at once. The sensory kind: burning, stabbing, electric, pins and needles, numbness, cold or hot feet, skin that hurts to touch, usually starting in the feet and hands but in the small fiber version often patchy and all over (face, trunk, scalp), because the damage can be scattered rather than length-dependent. And the autonomic kind: POTS, fainting, abnormal sweating, dry eyes and mouth, slow stomach, constipation or diarrhea, bladder trouble, erectile dysfunction, and heat intolerance.

That second list is why small fiber neuropathy is the thread running through the pots post here, the fibromyalgia post here (about half of people with fibromyalgia have it on biopsy), and the long COVID post here.

How it is actually diagnosed

  • Skin biopsy: a three-millimeter punch from the ankle and thigh, stained for nerve fibers and counted. This is the standard. A nerve fiber density below the fifth percentile for age and sex is the diagnosis.
  • QSART or sweat testing: measures the sweat response, which is run by small autonomic fibers.
  • Corneal confocal microscopy: counts small fibers in the cornea; non-invasive, increasingly available.
  • Quantitative sensory testing: threshold testing for temperature and pain.
  • Autonomic testing: tilt table, heart rate variability, the stand test.

If your doctor has only done nerve conduction, you have not had the test that would find this.

Why small fibers get damaged

This is the useful part. About half of cases are labeled idiopathic, which means nobody looked hard enough, because the list of findable causes is long and most of them are treatable.

Metabolic

  • Diabetes and prediabetes. The single most common cause, and small fibers are damaged by impaired glucose tolerance years before diabetes is diagnosed. A two-hour glucose tolerance test finds what a fasting glucose misses. The metabolic slide here.
  • Vitamin B12 deficiency, including the functional kind with a "normal" serum B12 and a high methylmalonic acid. Metformin, acid blockers, nitrous oxide, and vegan diets are the usual drivers.
  • Vitamin B6, both too little and too much. B6 deficiency damages nerves; so does B6 excess, above about 100 mg a day for months (and in sensitive people at lower doses), a common finding in people taking multiple supplements that each contain it.
  • Thiamine (B1), especially with alcohol, bariatric surgery, SIBO, diuretics, or a high-carbohydrate diet.
  • Copper deficiency (from zinc supplements, bariatric surgery, or malabsorption), which mimics B12 deficiency.
  • Vitamin E and folate less commonly.
  • Thyroid disease, both directions.

Immune

  • Sjögren's syndrome, which presents with dry eyes and mouth and is a leading immune cause; the antibodies are often negative and a lip biopsy may be needed.
  • Celiac disease, which causes neuropathy with or without gut symptoms.
  • Sarcoidosis, lupus, and other connective tissue diseases.
  • Post-infectious and post-COVID small fiber neuropathy, now well documented, probably immune-mediated.
  • Autoantibodies against nerve targets (TS-HDS, FGFR3, plexin D1), which are found in a meaningful fraction of "idiopathic" cases and point toward immune treatment.

Toxic and drug-related

Alcohol, chemotherapy, fluoroquinolone antibiotics (the fluoroquinolone post here), statins in some people, metronidazole, and heavy metals.

Genetic

Variants in the sodium channels that small fibers use (SCN9A, SCN10A, SCN11A) explain a share of "idiopathic" cases, including some families with burning pain from childhood. Transthyretin amyloidosis is rare but treatable and worth knowing about. Hypermobile connective tissue disorders have a high rate of small fiber neuropathy for reasons that are still being worked out; the connective tissue post here.

Mast cell activation

Mast cells sit next to nerve endings and release histamine, tryptase, and nerve growth factor, all of which sensitize and, over time, damage small fibers. The overlap between MCAS, POTS, and small fiber neuropathy is large enough that finding one means looking for the others. The mast cell post here.

If the model is right, what the research points to

The first step is not a supplement. It is the biopsy and the cause list, because treating the cause is what lets nerves regrow, and small fibers do regrow, slowly, at about a millimeter a day, over months to a few years.

  1. Get the right test. Skin biopsy or corneal confocal microscopy through a neurologist, and the stand test at home.
  2. Run the cause panel. Two-hour glucose tolerance test with insulin, HbA1c; methylmalonic acid and B12; plasma B6 (P5P), both for deficiency and for excess; whole-blood thiamine; copper and ceruloplasmin; thyroid panel; celiac antibodies; Sjögren's antibodies (SSA, SSB) and ANA; serum protein electrophoresis; and, if the first round is negative, the TS-HDS and FGFR3 antibody panel and genetic testing. The lab guide here.
  3. Treat what you find. Glucose control (the strongest evidence for stopping progression), B12 as hydroxocobalamin plus adenosylcobalamin, thiamine or benfotiamine, stopping excess B6, copper if low, gluten-free if celiac, immune treatment through a specialist if the immune markers are positive (IVIG has helped in antibody-positive and Sjögren's-related cases in small studies).
  4. Feed regrowth. The nutrients small fibers are built from: B12, thiamine, the omega-3 fats, acetyl-L-carnitine (which has trial support in diabetic and chemotherapy neuropathy for pain and regrowth), alpha-lipoic acid (600 mg, with the strongest nutrient evidence in diabetic neuropathy; not in pregnancy, planning, or breastfeeding), and enough protein. The pots post lays out the order.
  5. Calm the pain signal while the nerves repair. Topical capsaicin (the high-dose patch has trial support), topical lidocaine, and the prescription options (gabapentin, pregabalin, duloxetine, low-dose naltrexone, which has growing evidence in small fiber neuropathy and fibromyalgia) through a clinician. Magnesium and glycine help the sensitized spinal cord.
  6. Treat the mast cells if the picture fits: the four-week low-histamine trial here and the stabilizers.
  7. Manage the autonomic side with the POTS levers: salt, fluids, compression, the breathing practice, recumbent exercise.
  8. Protect what is left. No alcohol, no fluoroquinolones unless there is no alternative, careful with any supplement containing B6, feet checked and shoes that fit, because numb feet get injured.

What to expect

With the cause treated, pain usually improves within three to six months and nerve density on repeat biopsy improves over one to two years. Without the cause found, the usual course is slow worsening with symptom management only. That difference is the argument for the biopsy and the panel, and for not accepting "idiopathic" until the list has been worked through.

Educational content written from a research perspective, not medical advice. I am a PhD scientist, not a physician, and I do not diagnose, treat, cure, or prevent disease. Skin biopsy, immune testing, and all prescription treatment go through a neurologist or your own clinician.

Definition and epidemiology

Small fiber neuropathy (SFN) is damage to thinly myelinated A-delta and unmyelinated C fibers, producing somatic symptoms (burning, lancinating, and electric pain, allodynia, paresthesia, thermal dysesthesia) and autonomic symptoms (orthostatic intolerance and POTS, sudomotor dysfunction, sicca, gastroparesis, bowel and bladder dysfunction, erectile dysfunction, heat intolerance). Distribution is length-dependent in metabolic causes and frequently non-length-dependent (patchy, proximal, facial, truncal) in immune and genetic causes. Prevalence is estimated at 50 per 100,000 and rising with recognition. Nerve conduction studies assess large fibers only and are normal by definition in pure SFN. Intraepidermal nerve fiber density (IENFD) reduction is found in roughly 40 to 60 percent of fibromyalgia cohorts (Oaklander 2013, Üçeyler 2013, and subsequent series), in a substantial fraction of POTS (particularly the neuropathic subtype), and in post-COVID neuropathic and dysautonomic presentations.

Diagnosis

  • Skin biopsy (3 mm punch, distal leg 10 cm above the lateral malleolus and proximal thigh, PGP9.5 immunostaining, IENFD against age- and sex-normed fifth percentile values; the EFNS/PNS and Lauria normative data). Proximal to distal ratio helps distinguish length-dependent from non-length-dependent patterns; sweat gland nerve fiber density adds autonomic information.
  • Corneal confocal microscopy: corneal nerve fiber length and density; non-invasive, correlates with IENFD, sensitive to early diabetic and immune SFN.
  • Sudomotor testing: QSART, thermoregulatory sweat test, electrochemical skin conductance (Sudoscan).
  • Quantitative sensory testing: thermal and mechanical thresholds; supportive, operator-dependent.
  • Autonomic testing: active stand and tilt, heart rate variability, Valsalva, supine and standing catecholamines.
  • Diagnostic criteria: the Besta criteria (clinical signs plus abnormal IENFD or QST) and the 2019 Devigili and Lauria framework; probable SFN with clinical features and one abnormal test, definite with two.

Etiologic work-up

Roughly half of SFN is labeled idiopathic in series where the work-up is limited; systematic evaluation reduces that fraction substantially (de Greef 2018 found a cause in about 47 percent with a broad panel; later series with autoantibody and genetic testing push further).

Metabolic and nutritional

Cause Mechanism Test Note
Diabetes and impaired glucose tolerance Polyol flux, AGE formation, microvascular ischemia, mitochondrial dysfunction 2-hour OGTT with insulin (fasting glucose and HbA1c miss IGT); HbA1c IGT is found in 30 to 50 percent of "idiopathic" painful neuropathy; the metabolic slide here
Cobalamin deficiency, including functional Impaired methionine synthase, methylmalonyl-CoA mutase; myelin and axonal transport MMA, holotranscobalamin, homocysteine; serum B12 is insensitive between 200 and 400 pg/mL Metformin, PPIs, nitrous oxide, vegan diet, pernicious anemia
Pyridoxine deficiency and excess Deficiency: impaired sphingolipid and neurotransmitter synthesis; excess: sensory ganglionopathy Plasma PLP (deficient under 20 nmol/L; toxicity risk with supplementation over 100 mg daily, reported at lower doses in susceptible individuals) Multi-ingredient supplements are the common excess source
Thiamine deficiency Impaired transketolase, PDH, alpha-KGDH; energy failure in axons Whole-blood TDP, erythrocyte transketolase activation Alcohol, bariatric surgery, SIBO, diuretics, high-carbohydrate diet
Copper deficiency Cytochrome c oxidase, myelination Serum copper, ceruloplasmin, plasma zinc Zinc supplementation, bariatric surgery, malabsorption; mimics B12 myeloneuropathy
Vitamin E, folate deficiency Antioxidant, one-carbon Plasma alpha-tocopherol, RBC folate Malabsorption
Thyroid dysfunction Metabolic and compressive TSH, free T4, free T3, antibodies
Renal and hepatic disease Uremic and cholestatic Creatinine, eGFR, LFTs

Immune-mediated

Sjögren's syndrome (a leading immune cause; SSA and SSB antibodies are negative in a substantial fraction, so minor salivary gland biopsy is indicated when sicca is present), celiac disease (tTG-IgA with total IgA; neuropathy with or without enteropathy), sarcoidosis (ACE, chest imaging), systemic lupus and other connective tissue diseases, monoclonal gammopathy (SPEP with immunofixation, free light chains), paraneoplastic (rare in pure SFN), and autoantibodies against trisulfated heparan disaccharide (TS-HDS) and fibroblast growth factor receptor 3 (FGFR3), found in roughly a third to half of otherwise idiopathic SFN in several series, with plexin D1 antibodies described more recently. Post-infectious and post-COVID SFN is documented by skin biopsy and is presumed immune-mediated; a majority of patients in small series improved with IVIG.

Toxic and iatrogenic

Alcohol (direct and thiamine-mediated), platinum and taxane chemotherapy, bortezomib, fluoroquinolones (the fluoroquinolone post here), metronidazole, nitrofurantoin, isoniazid without pyridoxine, statins (uncommon, reversible), amiodarone, heavy metals (arsenic, thallium, mercury), and excess pyridoxine as above.

Genetic

Gain-of-function variants in SCN9A (Nav1.7), SCN10A (Nav1.8), and SCN11A (Nav1.9) account for roughly 10 to 15 percent of idiopathic SFN in sequencing series and are associated with early onset, burning pain, and autonomic features; sodium channel blockers (lacosamide, carbamazepine, mexiletine) have mechanistic rationale and small trial support in these patients. Transthyretin amyloidosis (TTR sequencing; treatable with stabilizers and gene-silencing agents) and Fabry disease (alpha-galactosidase A; treatable) are rare but critical to identify. Hereditary sensory and autonomic neuropathies. Hypermobile EDS and HSD carry a high SFN prevalence (Cazzato 2016: reduced IENFD in all 20 EDS patients studied), with mechanisms under investigation (extracellular matrix, mast cell, and mechanical contributions); the connective tissue post here.

Mast cell activation

Mast cells are apposed to peripheral nerve terminals; their mediators (histamine, tryptase via PAR2, NGF, PGD2, TNF, IL-6) sensitize and, with chronic exposure, injure small fibers; mast cell density is increased in SFN and fibromyalgia skin. The clinical triad of SFN, POTS, and MCAS is common enough that identifying one warrants screening for the others; the mast cell post here.

What the literature suggests for each node

  1. Establish the diagnosis by skin biopsy or corneal confocal microscopy; document autonomic involvement with sudomotor and cardiovascular testing. Grade A for diagnostic utility.
  2. Complete the etiologic panel: OGTT with insulin, HbA1c, MMA and holoTC, PLP, whole-blood TDP, copper and ceruloplasmin, vitamin E, RBC folate, thyroid panel, celiac serology, SSA and SSB and ANA, ACE, SPEP with immunofixation and free light chains, HIV and hepatitis serology where indicated, then TS-HDS and FGFR3 antibodies and SCN9A, SCN10A, SCN11A, TTR, and GLA sequencing in the unexplained. The lab guide here carries assay notes.
  3. Treat the cause. Glycemic control slows progression and improves IENFD in IGT with lifestyle intervention (Smith 2006: IENFD improved with diet and exercise); cobalamin as hydroxocobalamin plus adenosylcobalamin (parenteral where MMA is high and absorption uncertain); thiamine or benfotiamine 300 mg; withdrawal of pyridoxine excess; copper repletion; gluten-free diet in celiac neuropathy (improves symptoms and conduction in series); immunotherapy by a neurologist in Sjögren's, sarcoid, antibody-positive, and post-infectious SFN (IVIG improved pain and IENFD in several open-label series; a 2021 RCT in idiopathic SFN without antibody selection was negative, which argues for selecting by marker). Grade A to B depending on cause.
  4. Support regeneration. Acetyl-L-carnitine 500 to 1,000 mg twice daily (RCTs in diabetic and chemotherapy-induced neuropathy show reduced pain and increased fiber regeneration; Grade B); alpha-lipoic acid 600 mg daily (multiple RCTs in diabetic neuropathy, NATHAN 1 and SYDNEY; Grade A in that population; excluded in pregnancy, conception planning, and lactation by this site's convention); omega-3 EPA and DHA 2 to 3 g (small trials with corneal nerve regeneration in diabetes; Grade B); vitamin D repletion (associated with pain reduction in deficient diabetic neuropathy; Grade C); adequate protein and B-complex status. Regeneration proceeds at roughly 1 mm per day; IENFD improvement is measurable at 12 to 24 months.
  5. Symptomatic control: topical 8 percent capsaicin (Grade A), topical lidocaine (Grade B), gabapentin or pregabalin (A), duloxetine (A), tricyclics (A), low-dose naltrexone 1.5 to 4.5 mg (small RCTs and series in fibromyalgia and SFN; Grade B), sodium channel blockers in SCN-variant cases, magnesium and glycine for spinal sensitization (B), and avoidance of opioids except under specialist care.
  6. Mast cell measures where the phenotype fits: the low-histamine trial here, H1 and H2 antagonists, ketotifen, cromolyn; the mast cell post.
  7. Autonomic management per the pots post here: volume, salt, compression, slow breathing, recumbent-to-upright exercise progression, pyridostigmine and midodrine by clinician.
  8. Protection: alcohol abstinence, fluoroquinolone avoidance, supplement audit for cumulative pyridoxine, foot care, and screening for the comorbid conditions (apnea, iron deficiency, thyroid disease) that lower pain threshold.

Markers that test the model

Pain and autonomic symptom scores (SFN-SIQ, COMPASS-31) monthly; the metabolic and nutritional panel at 12 weeks; repeat skin biopsy or corneal confocal microscopy at 12 to 24 months for regeneration; standing heart rate and HRV; sudomotor retesting where available.

Educational and research content, not medical advice. The author holds a PhD in cellular and molecular nutrition, is not a licensed physician, and does not diagnose, treat, cure, or prevent disease. Diagnostic testing, immunotherapy, and all prescription treatment are decided by a neurologist or the treating clinician.